B37.0
Conditions
Interventions
Group 1: In the test group, two breath samples are collected from the patient. The first breath sample is collected before the start of antifungal therapy, the second breath sample is collected after
Sponsors
Charité Campus Charité Mitte
Eligibility
Sex/Gender
All
Age
18 Years to 95 Years
Inclusion criteria
Inclusion criteria: - Ability (verbal, physically and mentally) to understand the nature of the study and to participate - Willingness to study participation - Completed and signed informed consent - Age between 18 and 95 years - Non-Smokers (for = 5 years) - endentulous participants wearing complete dentures (incl. implant-assisted prostheses without signs of periimplant infections) Specific inclusion criteria Test group (n=10) - confirmation of diagnosis assumed from clinical signs of candida infection - patients prior to antifungal therapy according to microbiological results Control group (n=10) - no signs of clinical symptoms of a candida infection
Exclusion criteria
Exclusion criteria: - Previous malignancies (=5 years) - Severe internal comorbidities (myocardial infarction, cardiomyopathy, NYHA functional class III / IV, severe COPD, renal failure, Diabetes mellitus with HbA1c =7.0%, ASA class =3) - Drug addiction, incl. Alcohol - smokers, ex-smokers < 5 years - Patients under 18 years old - Patients over 70 years - Participation in a similar study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detectable Candida-specific signature VOCs (volatile organic compounds) at diagnosis with the help of gas chromatography and mass spectrometry | — |
Secondary
| Measure | Time frame |
|---|---|
| No detectable Candida-specific signature VOCs after antifungal therapy with the help of gas chromatography and mass spectrometry | — |
Countries
Germany
Contacts
Public ContactMoritz Hertel
Charité - Universitätsmedizin Berlin
Outcome results
None listed